23 July 2014

ASX ANNOUNCEMENT

Macquarie University Cancer Institute named for L-Dex international post-approval clinical study

HIGHLIGHTS

• Macquarie University Cancer Institute (MCI) in Sydney, New South Wales, Australia named as Australian site for post-approval study
• Esteemed Principal Investigators at Macquarie are Professor John Boyages, MD, PhD and Louise Koelmeyer, BAppSc
• Inclusion of such major research centres in this trial expected to drive further market adoption of ImpediMed’s L-Dex® device

Brisbane, Australia –ImpediMed Limited (ASX: IPD) (“the Company”) is pleased to announce that Macquarie University Cancer Institute (MCI) in Sydney, Australia has been named as the Australian site for its international, post-approval clinical study.

The Macquarie University Cancer Institute (MCI) is leading Australian research in all aspects of lymphoedema. Macquarie University is renowned for its interdisciplinary research having been awarded five stars in the international QS Stars rating system, one of only five Australian universities to receive five stars in all categories. This world-class institution works within Australia’s only high-technology private hospital owned and operated by a university and is part of the Australian School of Advanced Medicine, the University’s postgraduate medical research and teaching school.

Professor Boyages is the Director of Macquarie University Cancer Institute (MCI) and Professor of Breast Oncology. He is a cancer specialist with 30 years of experience in the diagnosis and treatment of breast cancer. He was the founding director of the Westmead Breast Cancer Institute, has published more than 135 research and clinical articles, and is committed to the dissemination of research findings to lay and professional audiences.

Louise Koelmeyer is an occupational therapist with over 23 years of clinical experience in both public and private settings specializing in breast cancer rehabilitation and lymphoedema management in all areas of assessment, education, early detection and treatment. She has a strong passion for achieving best practice in lymphoedema management in both the physical and psychosocial aspects of treatment and has supported this by being an active and committed member on several Australasian Lymphology Association (ALA) committees, as well as presenting papers and posters at conferences.

Louise also oversees the coordination of Survivorship programs at MCI, including the Advanced Lymphoedema Surgical Program offering liposuction and lymph node transfer techniques. “I am very confident that we will make a good partnership together in achieving best practice for women at risk of lymphoedema to have access to early intervention programs. I am very excited about this project,” said Louise about this new study.
The purpose of the study is to objectively establish the clinical utility of ImpediMed’s L-Dex device, used for the early detection of lymphoedema. This study marks a new phase in ImpediMed’s commercial rollout of L-Dex, with interim data from the trial to be used as the company seeks coverage from private health insurers in the US. The inclusion of major cancer centres in the study will also drive market adoption as the CPT® Category 1 Code (government pay code) comes into effect on 1 January 2015.

“We are very excited to add Macquarie Cancer Institute, home to some of the world’s most pre-eminent researchers, such as Professor Boyages, and Louise Koelmeyer, to this trial” said Richard Carreon, President and CEO of ImpediMed.

Details of the clinical trial can be found at the US National Institutes of Health website: http://clinicaltrials.gov/ct2/show/NCT02167659?term=impedimed&rank=6

Richard Carreon
CEO

ENDS
For further information contact: Richard Carreon, ImpediMed CEO
Morten Vigeland, ImpediMed CFO
T: +1 (760) 585-2100

Kyahn Williamson, Buchan
Investor and Media Relations
T: +61 3 9866 4722
E: kwilliamson@buchanwe.com.au

About ImpediMed
ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

For more information, visit: www.impedimed.com.au